143B
|
IC50 |
16.88 μM
Compound: Cytarabine
|
Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
143B
|
IC50 |
2.06 μM
Compound: Cytarabine
|
Cytotoxicity against human 143B cells after 72 hrs by SRB assay
Cytotoxicity against human 143B cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
A549
|
GI50 |
|
Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
|
[PMID: 22264170]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32663707]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
A549
|
IC50 |
1.9 μM
Compound: 2, Ara-C
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 24956556]
|
A549
|
IC50 |
1.9 μM
Compound: 1, ara-C
|
Cytotoxicity against human A549 cells by sulforhodamine B method
Cytotoxicity against human A549 cells by sulforhodamine B method
|
[PMID: 19691349]
|
A549
|
IC50 |
|
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
A549
|
IC50 |
49.27 μg/mL
Compound: CAR
|
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 35963130]
|
A549
|
IC50 |
620 μM
Compound: cytarabine
|
Cytotoxicity against A549 cells after 72 hrs by SRB assay
Cytotoxicity against A549 cells after 72 hrs by SRB assay
|
[PMID: 17419604]
|
B16
|
IC50 |
30.62 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
B16
|
IC50 |
49.22 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
|
10.1039/C0MD00208A
|
BALL-1
|
GI50 |
|
Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
|
[PMID: 22264170]
|
Bel-7402
|
IC50 |
|
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 20692841]
|
CCRF S-180
|
ED50 |
|
Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
|
[PMID: 1652024]
|
CCRF S-180
|
IC50 |
25.43 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
CCRF S-180
|
IC50 |
40.33 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
|
10.1039/C0MD00208A
|
CCRF-CEM
|
IC50 |
0.001 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
|
[PMID: 19674903]
|
CCRF-CEM
|
EC50 |
0.005614 μM
Compound: cytarabine
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
|
[PMID: 22582991]
|
CCRF-CEM
|
ED50 |
|
Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
|
[PMID: 1652024]
|
CCRF-CEM
|
EC50 |
0.0228 μM
Compound: cytarabine
|
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
CCRF-CEM
|
IC50 |
0.024 μM
Compound: cytarabine
|
Cytotoxicity against human CEM cells after 2 days
Cytotoxicity against human CEM cells after 2 days
|
[PMID: 19910080]
|
CCRF-CEM
|
IC50 |
0.024 μM
Compound: ara-C, cytarabine
|
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
|
[PMID: 20000418]
|
CCRF-HSB-2
|
IC50 |
0.017 μg/mL
Compound: AraC
|
Growth inhibition of human CCRF-HSB-2 cells by MTT method
Growth inhibition of human CCRF-HSB-2 cells by MTT method
|
[PMID: 18819815]
|
CCRF-HSB-2
|
IC50 |
0.017 μg/mL
Compound: Ara-C
|
Antitumor activity against human CCRF-HSB2 cells by MTT assay
Antitumor activity against human CCRF-HSB2 cells by MTT assay
|
[PMID: 18723355]
|
CCRF-HSB-2
|
IC50 |
0.047 μg/mL
Compound: Ara-C
|
Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
|
[PMID: 17644399]
|
CCRF-HSB-2
|
IC50 |
0.047 μg/mL
Compound: Ara-C
|
Antitumor activity against human CCRF-HSB2 cells by MTT assay
Antitumor activity against human CCRF-HSB2 cells by MTT assay
|
[PMID: 17962027]
|
CCRF-HSB-2
|
IC50 |
|
Growth inhibition of human CCRF-HSB-2 cells by MTT assay
Growth inhibition of human CCRF-HSB-2 cells by MTT assay
|
[PMID: 17049252]
|
H22
|
IC50 |
25.98 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
H22
|
IC50 |
37.82 μM
Compound: Cytarabine
|
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
|
10.1039/C0MD00208A
|
HCT-116
|
IC50 |
|
Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 20211564]
|
HCT-116
|
GI50 |
|
Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
|
[PMID: 22264170]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
HCT-116
|
IC50 |
5.3 μM
Compound: 2, Ara-C
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 24956556]
|
HCT-116
|
IC50 |
5.3 μM
Compound: 1, ara-C
|
Cytotoxicity against human HCT116 cells by sulforhodamine B method
Cytotoxicity against human HCT116 cells by sulforhodamine B method
|
[PMID: 19691349]
|
HeLa
|
ED50 |
0.05 μg/mL
Compound: AraC
|
Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
|
[PMID: 178873]
|
HeLa
|
GI50 |
|
Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
|
[PMID: 22264170]
|
HeLa
|
IC50 |
0.26 μM
Compound: ara-C, cytarabine
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
|
[PMID: 20000418]
|
HeLa
|
IC50 |
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HeLa
|
IC50 |
3.54 μM
Compound: Cytarabine
|
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
HeLa
|
IC50 |
3.54 μM
Compound: Cytarabine
|
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 23867603]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
HeLa
|
IC50 |
464.433 μM
Compound: Ara-C, Cytarabine
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 19321234]
|
HeLa S3
|
ED50 |
2.13 μg/mL
Compound: cytosine arabinoside
|
Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
|
[PMID: 1800632]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 20692841]
|
HepG2
|
IC50 |
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HepG2
|
IC50 |
2.86 μM
Compound: Cytarabine
|
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
HepG2
|
IC50 |
26.23 μM
Compound: Cytarabine
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
HepG2
|
IC50 |
38.1 μM
Compound: Cytarabine
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
10.1039/C0MD00208A
|
HL-60
|
IC50 |
|
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
|
[PMID: 22582991]
|
HL-60
|
IC50 |
0.118 μM
Compound: Ara-C, Cytarabine
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 19321234]
|
HL-60
|
EC50 |
0.6572 μM
Compound: cytarabine
|
Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
HL60/MX2
|
EC50 |
0.2612 μM
Compound: cytarabine
|
Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
HT-29
|
IC50 |
66 nM
Compound: cytosine arabinoside
|
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 2778449]
|
HUVEC
|
GI50 |
|
Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
|
[PMID: 22264170]
|
K562
|
IC50 |
0.05 μM
Compound: 2, Ara-C
|
Cytotoxicity against human K562 cells by SRB assay
Cytotoxicity against human K562 cells by SRB assay
|
[PMID: 24956556]
|
K562
|
IC50 |
0.05 μM
Compound: 1, ara-C
|
Cytotoxicity against human K562 cells by sulforhodamine B method
Cytotoxicity against human K562 cells by sulforhodamine B method
|
[PMID: 19691349]
|
K562
|
IC50 |
|
Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
|
[PMID: 22582991]
|
K562
|
IC50 |
24.29 μM
Compound: Cytarabine
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
K562
|
IC50 |
|
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 20692841]
|
K562
|
IC50 |
43.61 μM
Compound: Cytarabine
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
10.1039/C0MD00208A
|
KB
|
IC50 |
0.14 μg/mL
Compound: Ara-C
|
Growth inhibition of human KB cells by MTT assay
Growth inhibition of human KB cells by MTT assay
|
[PMID: 18055068]
|
KB
|
IC50 |
0.23 μg/mL
Compound: Ara-C
|
Antitumor activity against human KB cells by modified MTT assay
Antitumor activity against human KB cells by modified MTT assay
|
[PMID: 17644399]
|
KB
|
IC50 |
0.23 μg/mL
Compound: Ara-C
|
Antitumor activity against human KB cells by MTT assay
Antitumor activity against human KB cells by MTT assay
|
[PMID: 17962027]
|
KB
|
IC50 |
0.42 μg/mL
Compound: AraC
|
Growth inhibition of human KB cells by MTT method
Growth inhibition of human KB cells by MTT method
|
[PMID: 18819815]
|
KB
|
IC50 |
|
Growth inhibition of human KB cells by MTT assay
Growth inhibition of human KB cells by MTT assay
|
[PMID: 17049252]
|
KB
|
IC50 |
0.73 μg/mL
Compound: Ara-C
|
Antitumor activity against human KB cells by MTT assay
Antitumor activity against human KB cells by MTT assay
|
[PMID: 18723355]
|
KB
|
IC50 |
0.99 μg/mL
Compound: Cytarabine
|
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 21945463]
|
KB
|
ED50 |
2.84 μg/mL
Compound: cytosine arabinoside
|
Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
|
[PMID: 1800632]
|
KB
|
IC50 |
|
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
KB
|
IC50 |
4.07 μM
Compound: Cytarabine
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
KB
|
IC50 |
4.07 μM
Compound: Cytarabine
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 23867603]
|
KB
|
IC50 |
|
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
L02
|
IC50 |
|
Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 29886320]
|
L02
|
IC50 |
|
Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
|
[PMID: 30852384]
|
L1210
|
IC50 |
0.0004 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
|
[PMID: 19674903]
|
L1210
|
IC50 |
0.024 μM
Compound: cytarabine
|
Cytotoxicity against mouse L1210 cells after 2 days
Cytotoxicity against mouse L1210 cells after 2 days
|
[PMID: 19910080]
|
L1210
|
IC50 |
0.024 μM
Compound: ara-C, cytarabine
|
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
|
[PMID: 20000418]
|
L1210
|
ED50 |
|
Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
|
[PMID: 1652024]
|
L1210
|
ED50 |
|
Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
|
[PMID: 118258]
|
L1210
|
ED50 |
|
In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
|
[PMID: 3968680]
|
L1210
|
IC50 |
103 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
|
[PMID: 19674903]
|
L1210
|
ED50 |
2.76 μg/mL
Compound: cytosine arabinoside
|
Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
|
[PMID: 1800632]
|
MCF7
|
IC50 |
> 20 μM
Compound: Cytarabine
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
|
[PMID: 35665692]
|
MCF7
|
IC50 |
|
Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 20211564]
|
MCF7
|
IC50 |
0.004 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
|
[PMID: 19674903]
|
MCF7
|
IC50 |
0.04 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
|
[PMID: 19674903]
|
MCF7
|
IC50 |
0.93 μg/mL
Compound: Cytarabine
|
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 21945463]
|
MCF7
|
IC50 |
3.82 μM
Compound: Cytarabine
|
Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
|
[PMID: 27073055]
|
MCF7
|
IC50 |
3.82 μM
Compound: Cytarabine
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 23867603]
|
MCF7
|
IC50 |
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
MDA-MB-231
|
IC50 |
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
MDA-MB-231
|
IC50 |
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
MES-SA
|
IC50 |
1.7 μM
Compound: AraC, cytarabine
|
Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
|
[PMID: 19674903]
|
MOLT-3
|
ED50 |
2.67 μg/mL
Compound: cytosine arabinoside
|
Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
|
[PMID: 1800632]
|
MOLT-4
|
IC50 |
|
Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
|
[PMID: 20211564]
|
MV4-11
|
IC50 |
|
Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
|
[PMID: 20153646]
|
NCI-H460
|
IC50 |
|
Antitumor activity against human H460 cells after 24 hrs by MTT assay
Antitumor activity against human H460 cells after 24 hrs by MTT assay
|
[PMID: 20211564]
|
NHDF
|
IC50 |
|
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
NHDF
|
IC50 |
|
Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
NUGC-3
|
GI50 |
|
Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
|
[PMID: 22264170]
|
P388
|
ED50 |
|
Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
|
[PMID: 1652024]
|
P388
|
IC50 |
1233 nM
Compound: cytosine arabinoside
|
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 2778449]
|
PC-3
|
IC50 |
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32663707]
|
PC-3
|
IC50 |
|
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
PC-3
|
IC50 |
|
Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
PC-3
|
IC50 |
55.9 μM
Compound: 2, Ara-C
|
Cytotoxicity against human PC3 cells by SRB assay
Cytotoxicity against human PC3 cells by SRB assay
|
[PMID: 24956556]
|
PC-3
|
IC50 |
55.9 μM
Compound: 1, ara-C
|
Cytotoxicity against human PC3 cells by sulforhodamine B method
Cytotoxicity against human PC3 cells by sulforhodamine B method
|
[PMID: 19691349]
|
RS4-11
|
IC50 |
|
Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
|
[PMID: 20153646]
|
SF-268
|
IC50 |
7.68 nM
Compound: Cytarabine
|
Cytotoxicity against human SF268 cells by MTT assay
Cytotoxicity against human SF268 cells by MTT assay
|
[PMID: 19345581]
|
SF-268
|
IC50 |
7.68 μM
Compound: Cytarabine
|
Cytotoxicity against human SF268 cells after 3 days by MTT assay
Cytotoxicity against human SF268 cells after 3 days by MTT assay
|
[PMID: 20356655]
|
SK-BR-3
|
IC50 |
|
Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32663707]
|
SK-HEP1
|
IC50 |
|
Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
SK-HEP1
|
IC50 |
|
Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
SK-OV-3
|
IC50 |
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32663707]
|
SMMC-7721
|
IC50 |
|
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 29886320]
|
SMMC-7721
|
IC50 |
|
Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
|
[PMID: 30852384]
|
SNU-638
|
IC50 |
0.15 μM
Compound: 2, Ara-C
|
Cytotoxicity against human SNU638 cells by SRB assay
Cytotoxicity against human SNU638 cells by SRB assay
|
[PMID: 24956556]
|
SNU-638
|
IC50 |
0.15 μM
Compound: 1, ara-C
|
Cytotoxicity against human SNU638 cells by sulforhodamine B method
Cytotoxicity against human SNU638 cells by sulforhodamine B method
|
[PMID: 19691349]
|
SNU-638
|
IC50 |
|
Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
|
[PMID: 29906687]
|
SNU-638
|
IC50 |
|
Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
|
[PMID: 26010585]
|
SW1573
|
IC50 |
10500 μM
Compound: cytarabine
|
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
|
[PMID: 17419604]
|
SW480
|
ED50 |
3.42 μg/mL
Compound: cytosine arabinoside
|
Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
|
[PMID: 1800632]
|
SW-620
|
IC50 |
|
Antitumor activity against human SW620 cells after 24 hrs by MTT assay
Antitumor activity against human SW620 cells after 24 hrs by MTT assay
|
[PMID: 20211564]
|
T47D
|
IC50 |
2.7 μM
Compound: 1, ara-C
|
Cytotoxicity against human T47D cells by sulforhodamine B method
Cytotoxicity against human T47D cells by sulforhodamine B method
|
[PMID: 19691349]
|
T47D
|
IC50 |
2.72 μM
Compound: 2, Ara-C
|
Cytotoxicity against human T47D cells by SRB assay
Cytotoxicity against human T47D cells by SRB assay
|
[PMID: 24956556]
|
U-87MG ATCC
|
CC50 |
|
Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
|
[PMID: 35123007]
|
U-87MG ATCC
|
IC50 |
|
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32663707]
|
U-87MG ATCC
|
IC50 |
|
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
U-937
|
IC50 |
0.002 μM
Compound: Cytarabine
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
|
[PMID: 30954427]
|
Vero
|
EC50 |
1.6 μg/mL
Compound: Ara-C
|
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
[PMID: 12444692]
|
Vero
|
EC50 |
|
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
[PMID: 12444692]
|
Vero
|
CC50 |
4.8 μg/mL
Compound: Ara-C
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
|
[PMID: 12444692]
|
WI-38
|
IC50 |
> 100 μg/mL
Compound: CAR
|
Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
|
[PMID: 35963130]
|